Tang Capital Management LLC
Tang Capital Management LLC reported 41 holdings worth US$2.2B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Tang Capital Management LLC reported 41 holdings worth US$2.2B as of Jun 30, 2026. Largest: Aurinia Pharmaceuticals Inc, Spyre Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 41
- Value as reported
- US$2.2B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Aurinia Pharmaceuticals Inc | 13M | US$221M | 10.1% |
| Spyre Therapeutics, Inc. | 1.89M | US$168M | 7.6% |
| Mirum Pharmaceuticals, Inc. | 1.24M | US$145M | 6.6% |
| Celcuity Inc. | 1.31M | US$138M | 6.2% |
| Corcept Therapeutics Incorporated | 1.5M | US$130M | 5.9% |
| Ptc Therapeutics, Inc. | 1.5M | US$122M | 5.6% |
| Lakefront Biotherapeutics | 3.79M | US$114M | 5.2% |
| Capricor Therapeutics, Inc. | 4.1M | US$98.7M | 4.5% |
| Tarsus Pharmaceuticals, Inc. | 1.57M | US$98.7M | 4.5% |
| Anaptysbio, Inc. | 1.33M | US$89.8M | 4.1% |
| Ani Pharmaceuticals, Inc. | 708K | US$58.6M | 2.7% |
| Compass Therapeutics, Inc. | 18M | US$39.4M | 1.8% |
| Precigen, Inc. | 6.42M | US$36.6M | 1.7% |
| Viridian Therapeutics, Inc. | 1.79M | US$32.9M | 1.5% |
| Nuvectis Pharma, Inc. | 1.55M | US$28.5M | 1.3% |
| Dianthus Therapeutics, Inc. | 265K | US$25.8M | 1.2% |
| Fulcrum Therapeutics, Inc. | 6.52M | US$23.9M | 1.1% |
| Atea Pharmaceuticals, Inc. | 4.81M | US$22.4M | 1.0% |
| Crescent Biopharma, Inc. | 1.16M | US$20.9M | 0.95% |
| Viking Therapeutics, Inc. | 500K | US$19.5M | 0.89% |
| Nuvation Bio Inc. | 3.3M | US$18.7M | 0.85% |
| Ideaya Biosciences, Inc. | 450K | US$16.8M | 0.76% |
| Journey Medical Corporation | 1.61M | US$11.4M | 0.52% |
| Insmed Incorporated | 100K | US$10.7M | 0.48% |
| Stoke Therapeutics, Inc. | 300K | US$9.82M | 0.45% |
| Pliant Therapeutics, Inc. | 6.14M | US$7M | 0.32% |
| Boundless Bio, Inc. | 2.56M | US$6.4M | 0.29% |
| Pmv Pharmaceuticals, Inc. | 4.25M | US$5.69M | 0.26% |
| Moderna, Inc. | 50,000 | US$3.5M | 0.16% |
| Heron Therapeutics, Inc. | 6.25M | US$2.67M | 0.12% |
| Lenz Therapeutics, Inc. | 451K | US$2.56M | 0.12% |
| Altimmune, Inc. | 666K | US$2.02M | 0.09% |
| Rocket Pharmaceuticals, Inc. | 100K | US$342K | 0.02% |
| Erasca, Inc. | 0 | US$0 | 0.00% |
| Evolus, Inc. Common Stock | 0 | US$0 | 0.00% |
| Fate Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Janux Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Kezar Life Sciences, Inc. | 0 | US$0 | 0.00% |
| Lexicon Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Neumora Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Nkarta, Inc. | 0 | US$0 | 0.00% |
| Abeona Therapeutics Inc. | 0 | US$0 | 0.00% |
| Agios Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Arvinas, Inc. | 0 | US$0 | 0.00% |
| Biogen Inc. | 0 | US$0 | 0.00% |
| Coherus Oncology, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related